InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology

Point-of-care regenerative cell therapy demonstrates promising safety and tolerability profile and closure of venous chronic leg wounds as conducted by Technical University Munich Houston, TX, USA and Munich, Germany, September 18, 2017 – InGeneron, Inc. today announced the publication of results from an investigator initiated case series in chronic leg wounds in the Journal of the European Academy of Dermatology and Venereology. In the case series, InGeneron’s proprietary adipose-derived regenerative cell (ADRC) technology was used for the treatment of chronic venous leg ulcers and mixed arterial-venous ulcers, the most common types of chronic leg wounds in the Western world, especially among elderly patients. Both conditions are associated with severe pain impairing quality of life and complex as well as time-consuming treatment regimes. The case series was conducted in collaboration with the Department of Dermatology at the University Hospital rechts der Isar Munich, led by Principal Investigator Alexander Konstantinow, MD, Dipl. Chem., and was published in the Journal of the European Academy of Dermatology and Venereology , one of the leading journals in its field. The publication titled “Therapy of ulcus cruris of venous and mixed venous arterial origin with autologous, adult native progenitor cells from subcutaneous adipose tissue: a prospective clinical pilot study” can be accessed through this link . “Chronic leg wounds are associated with a complicated disease progression and severe pain, impairing quality of life. Current treatment options are complex, time consuming and require high medical expenses. New therapeutic interventions that improve outcomes in these patients could have an important therapeutic impact,” said Alexander Konstantinow, MD, Dipl. Chem., senior physician at the Department of Dermatology and Allergology at Technical University Munich, Germany, and the primary investigator of the study. “The results that we have achieved in this case series are remarkable because we have been able to restore wound healing capabilities and decrease pain in multimorbid patients with large venous and mixed arterial-venous ulcers with an one-time minimally invasive application, while demonstrating a very good safety and tolerability profile. InGeneron’s point-of-care system has the potential to benefit a large number of patients with wound healing disorders of vascular origin, while being more cost effective compared to currently available standards of care.” The case series comprised 16 multimorbid leg ulcer patients (12 male, 4 female) ranging in age from 52 to 84 years who were treated with autologous ADRCs prepared at point-of-care with InGeneron’s Transpose® RT system. 7 patients were presenting with venous leg ulcers, 9 with mixed arterial-venous ulcers. Within 10 to 25 weeks, 11 out of the 16 patients showed complete wound closure. All 7 venous leg ulcers patients showed complete epithelialization. Moreover, the group of venous ulcer patients reported significant pain decrease by more than 90 percent 14 days post treatment. After 9 to 44 months of follow-up across all patients, no severe side effects were observed, demonstrating good overall safety and tolerability of the therapy in this patient population. “This case series marks the next step in our journey to establish clinical evidence of how adipose-derived regenerative cells impact inflammation and pain as well as support healing in chronic wounds,” said Ron Stubbers, President of InGeneron. “These encouraging results highlight the potential of our regenerative cell therapy approach in wound healing.” Based on the results of the investigator initiated study InGeneron plans to initiate a FDA feasibility study in the US in the near-term. The prospective, randomized, single-site study will investigate the safety and tolerability of InGeneron’s point-of-care regenerative cell therapy in venous leg ulcer patients. More information about the study can be found on www.clinicaltrials.gov or via this link . About the Transpose ® RT System and FDA approved clinical trials InGeneron’s Transpose ® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase ® , a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients’ own adipose tissue at point-of-care in less than 90 minutes for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance. The Transpose® RT System is being investigated in several FDA-approved clinical trials and is currently available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at www.clinicaltrials.gov under the identifiers NCT03752827 , NCT03513731 , and NCT03503305 . About InGeneron InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA. www.ingeneron.com Contacts: InGeneron, Inc. Eckhard Alt, MD, PhD Executive Chairman of InGeneron +1 (713) 440 9900 [email protected] Media Inquiries Jon Stone Stone Communications Consulting +1 (612) 475 5955 [email protected] Recent Posts Press Releases Feb 4, 2026 InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices Press Releases Jul 23, 2025 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System Press Releases Nov 13, 2023 InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears Press Releases Nov 3, 2023 InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial Press Releases Jan 6, 2023 New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups Press Releases Jan 24, 2022 InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics Press Releases Jan 6, 2022 American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears News Nov 23, 2021 InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body Press Releases Jul 23, 2021 InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment Press Releases Apr 7, 2020 InGeneron Announces Publication of Rotator Cuff Feasibility Study Press Releases Oct 31, 2019 InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure News Jun 11, 2019 InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic Press Releases May 15, 2019 InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy Press Releases Mar 21, 2019 InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration News Jan 23, 2019 InGeneron Expands Development Pipeline with Two Osteoarthritis Programs News Dec 12, 2018 InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy News Sep 18, 2017 InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology News Mar 6, 2017 InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies News Dec 5, 2016 InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences News Nov 21, 2016 InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS Have any Questions ? Important In the US InGeneron’s Transpose ® RT cell therapy platform is for investigational use only. By Clicking ‘Continue’ I confirm acknowledgment Continue Our mission is to enable novel, safe, and evidence-based therapies by unlocking the healing potential of each patient’s own regenerative cells. Twitter Linkedin Facebook 2 Youtube InGeneron, Inc. 8205 El Rio St Houston, TX 77054 USA +1 (713) 440 9900 [email protected] Subscribe to our Newsletter © 2026 by InGeneron, Inc. Site info . All rights reserved. Web Design & Development by BelugaLab Privacy Policy

The release as fetched from its publisher. ingeneron.com ↗